Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Last updated: June 19, 2022
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Not Recruiting

Phase

4

Condition

Leukemia

Multiple Myeloma

Kidney Failure

Treatment

N/A

Clinical Study ID

NCT05429515
HFR_MM
  • Ages 18-80
  • All Genders

Study Summary

In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 to 80 years old
  • new onset of multiple myeloma
  • acute kidney injury with eGFR < 15 ml/min/1.73m2 and need hemodialysis
  • biopsy-proven cast nephropathy or clinical diagnosis of cast nephropathy based onexclusion of other causes of acute kidney injury including post-renal obstruction,hypercalcaemia, amyloidosis, light-chain deposition disease, contrast media and drugnephropathy
  • serum light chain > 500 mg/L

Exclusion

Exclusion Criteria:

  • chronic kidney disease stage 3 to 5 (eGFR< 60 ml/min/1.73m2 for at least 3 months)
  • haemodynamics unstability
  • active bleeding
  • cardiovascular and cerebrovascular events in the last month
  • other malignant tumor
  • conditions not suitable to participate in the study, such as bad compliance

Study Design

Total Participants: 50
Study Start date:
July 01, 2022
Estimated Completion Date:
December 01, 2032

Study Description

In patients with multiple myeloma-related severe acute kidney injury, compare the renal outcome between patients receiving HFR-SUPRA and patients receiving hemodialysis. Both groups of patients receive chemotherapy.